PROTHERICS AND ASTRAZENECA ANNOUNCE LATE STAGE LICENSING AGREEMENT ON CYTOFAB FOR TREATMENT OF SEPSIS

Protherics, the biopharmaceutical company focused on critical care and oncology, today announces an agreement with AstraZeneca for the global development and commercialisation of Protherics' anti-sepsis product CytoFab. CytoFab is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).
Market Wire